# Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026
Canonical URL: https://biopharmsignal.com/news/GERN/geron-plans-to-announce-second-quarter-2026-financial-results-on-august-5-2026-cc0edc91
Ticker: GERN
Company: Geron
Source: Geron
Published: 2026-07-22 11:00 EST
## Summary

Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change...

## Article Body
Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company’s website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.

A live and archived audio webcast of the conference call will be available from the Investors and Media section of the Company’s website at www.geron.com .

About Geron Geron is a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer. Our first-in-class telomerase inhibitor RYTELO ® (imetelstat) is approved in the United States and the European Union for the treatment of certain adult patients with lower-risk myelodysplastic syndromes with transfusion dependent anemia. We are also conducting a pivotal Phase 3 clinical trial of imetelstat in JAK-inhibitor relapsed/refractory myelofibrosis, as well as studies in other hematologic malignancies. Inhibiting telomerase activity, which is increased in malignant stem and progenitor cells in the bone marrow, aims to potentially reduce proliferation and induce death of malignant cells. To learn more, visit www.geron.com or follow us on LinkedIn .

Investors and Media Dawn Schottlandt Senior Vice President, Investor Relations and Corporate Affairs dschottlandt@geron.com
## Recent Company News
- 2026-07-22 20:01 EST — [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-31c72267) — Source: Geron
- 2026-07-22 11:00 EST — [Geron Plans to Announce Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/GERN/geron-plans-to-announce-second-quarter-2026-financial-results-on-august-5-2026-cc0edc91) — Source: Geron
- 2026-07-14 20:26 EST — [Geron Corporation Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-dee5e3ab) — Source: Geron
- 2026-07-13 12:00 EST — [Geron Announces Appointment of Chinmaya Rath as Chief Business Officer](https://biopharmsignal.com/news/GERN/geron-announces-appointment-of-chinmaya-rath-as-chief-business-officer-bb96f9cb) — Source: Geron
- 2026-06-18 20:01 EST — [Geron Corporation Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/GERN/geron-corporation-reports-inducement-grants-under-nasdaq-listing-rule-5635-c-4-09abd3e0) — Source: Geron
## Related News
- 2026-07-28 13:00 EST — ENLV — [Enlivex Announces $400,000,000 Private Placement](https://biopharmsignal.com/news/ENLV/enlivex-announces-400-000-000-private-placement-20e71a7a)
- 2026-07-28 12:30 EST — XRAY — [Dentsply Sirona Advances Commercial Growth Strategy in Canada Through Expanded Medline Sinclair Relationship](https://biopharmsignal.com/news/XRAY/dentsply-sirona-advances-commercial-growth-strategy-in-canada-through-expanded-m-e2440bb2)
- 2026-07-28 12:30 EST — RLMD — [Relmada Therapeutics Appoints Uro-Oncology Leader Bipin Dalmia as Chief Business Officer](https://biopharmsignal.com/news/RLMD/relmada-therapeutics-appoints-uro-oncology-leader-bipin-dalmia-as-chief-business-5c4d7b11)
- 2026-07-28 12:05 EST — RIGL — [Rigel Announces Conference Call and Webcast to Report Second Quarter 2026 Financial Results](https://biopharmsignal.com/news/RIGL/rigel-announces-conference-call-and-webcast-to-report-second-quarter-2026-financ-5b987d7a)
- 2026-07-28 12:05 EST — GSK — [GSK to establish new flagship R&D centre on Cambridge Biomedical Campus, UK](https://biopharmsignal.com/news/GSK/gsk-to-establish-new-flagship-r-d-centre-on-cambridge-biomedical-campus-uk-6f2bb859)